Prostate cancer trials
Clinical drug trials play a vital role in moving new treatments to patients who need them most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow are currently over 90 phase iii drug trials and more than 400 phase i/ii trials in process for prostate cancer in north america and europe. Resources on this page can direct you to clinical trials that are currently open for enrollment in your local area, as well as across the country. View our faqs about clinical trials, please visit for the newsletterstay informed about the latest research in prostate leave this field te cancer clinical trials prostate cancer clinical trials consortium (pcctc) is a clinical research group sponsored by the prostate cancer foundation and the department of defense prostate cancer research program (pcrp), with its coordinating center headquartered at memorial sloan kettering cancer center. The pcctc is currently composed of 11 participating clinical research sites and 21 affiliated clinical research a complete list of open trials in the united states, please visit:A clinical research study for patients with prostate cancer that has not spread beyond the healthcare is seeking men who have prostate cancer to participate in a research study of an investigational drug. The purpose of the aramis trial is to determine the safety and effectiveness of an investigational drug in delaying prostate cancer spreading from the prostate. This study is enrolling patients with prostate cancer that is at risk of progressing, but has not already spread to other areas of the body. Eligible patients must have rising prostate specific antigen (psa) values without spread of their prostate cancer to other areas of the you are currently receiving hormone therapy, your treatment will continue and in addition you will receive either the investigational medication or placebo. Clinical research study is now enrolling for men who have high-risk, localized or locally advanced prostate cancer and are receiving radiation therapy. Janssen research & development is seeking men to participate in a clinical trial of an investigational drug for prostate cancer. The selections will be random, and the investigational medication will be given to 1 out of every 2 study identifier: n research & development, llc is part of the janssen pharmaceutical companies of johnson & and anti-tumor study of oral epi-506 for patients with metastatic castration-resistant prostate study will consist of 2 parts: part i (dose escalation) and part ii (dose expansion). Patients may be allowed to escalate sequentially to a higher dose cohort after twelve weeks of part ii, 3 patient populations; post-abiraterone metastatic castration-resistant prostate cancer (mcrpc) but enzalutamide-naïve, post-enzalutamide mcrpc but abiraterone-naïve, and post-abiraterone and enzalutamide mcrpc will be studied at the recommended phase 2 dose (rp2d) determined in part i over 12 weeks of daily dosing.
Epi-506&rank=onal open trials can be found by going to:Cancer clinical trials: a commonsense guide to experimental cancer therapies and clinical n from both a patient and clinician perspective by larry axmaker, ed. Beer, md, a pcf-funded researcher, this book is an insightful resource for anyone considering clinical trials in addition to standard cancer therapy. For your treatment teamtreatment rising to consider when your psa is rising after initial treatment for the majority of men, prostate cancer is treatable and curable and does.. Cancer foundation receives more than $5 million from the movember foundation 5 new challenge awards will fund investigations in lethal prostate cancer.. Iconicon indicating subtraction, or that the element can be iconicon indicating addition, or that the element can be (down) arrow icon, usually indicating that the containing element can be opened and te cancer signs & te cancer causes & risk te cancer iconicon indicating subtraction, or that the element can be iconicon indicating addition, or that the element can be (down) arrow icon, usually indicating that the containing element can be opened and test for prostate te cancer screening te cancer iconicon indicating subtraction, or that the element can be iconicon indicating addition, or that the element can be (down) arrow icon, usually indicating that the containing element can be opened and te biopsy te cancer iconicon indicating subtraction, or that the element can be iconicon indicating addition, or that the element can be (down) arrow icon, usually indicating that the containing element can be opened and surveillance for prostate l prostatectomy for prostate ion therapy for prostate therapy for prostate therapies for prostate beyond prostate al trials & research for prostate te cancer surgeons & al trials & research for prostate d arrow iconan arrowing pointing forward, usually indicating forward movement, or the ability the share something via social iconan icon showing an uppercase letter "x", indicating that this will close the current ok iconan icon representing the facebook social media r iconan icon representing the twitter social media in iconan icon representing the social media service pe iconan icon showing an envelope, usually indicating r iconan icon showing a printer, indicating the ability to print the associated of the reasons we know so much about prostate cancer and how best to treat it is that many of our researchers focus solely on this disease. Our busy research program means that we’re often able to offer men with all stages of prostate cancer access to clinical trials of new treatments, sometimes years before they’re widely trials test new drugs and drug combinations, surgical and radiation therapy techniques, diagnostic technologies, and strategies for preserving quality of life for men undergoing treatment. To learn more about a study, choose from the list by cancer type:Prostate cancer-localized disease [9]-metastatic disease after hormone-reducing therapy [18]-quality of life [14]-rising psa after primary therapy [6]. Phase i study of a vaccine-based immunotherapy (prca vbir) for prostate es: metastatic disease after hormone-reducing therapy, rising psa after primary ons: new york city. Phase i study of azd8186 with and without abiraterone acetate in men with advanced prostate es: metastatic disease after hormone-reducing ons: new york city. Phase i study of ec1169 in men with recurrent metastatic castration-resistant prostate es: metastatic disease after hormone-reducing ons: new york city. Phase i study of immunotherapy with iph2201 plus durvalumab in patients with metastatic solid es: cervical cancer, colon cancer, rectal cancer, pancreatic cancer, lung cancer, non-small cell, ovarian cancer, metastatic disease after hormone-reducing therapy, pancreatic cancer, uterine (endometrial) ons: new york city. Phase i study of radiation therapy to the prostate and the dominant prostate es: localized ons: new york city.
Phase i study of tas3681 in men with metastatic castration-resistant prostate es: metastatic disease after hormone-reducing ons: new york city. Phase i study of the immune activity and safety of imc-cs4 in patients with advanced breast or prostate es: breast cancer, metastatic disease after hormone-reducing ons: new york city. Phase i study of the radiopharmaceutical 131i-mip-1095 in men with advanced prostate es: metastatic disease after hormone-reducing ons: new york city. Phase i study of zen003694 plus enzalutamide in men with metastatic castration-resistant prostate es: metastatic disease after hormone-reducing ons: new york city. Phase i/ii study of cx-2009 to treat patients with inoperable or metastatic solid es: breast cancer, head & neck cancer, hepatobiliary, lung cancer, non-small cell, ovarian cancer, metastatic disease after hormone-reducing therapy, upper gastrointestinal, uterine (endometrial) ons: new york city, patient –fri, 8:30 am–5:30 pm, te cancer clinical trials clinical trials are ibe to our up-to-date on the latest news about prostate cancer. Most treatments we use today for prostate cancer are the results of past clinical trials. It is important to ask and learn about clinical trials when you are making a treatment decision, it may be an option for ipating in a clinical trial is a way to gain access to promising and perhaps effective drugs yet to be approved by the fda. Clinical trials also test whether a new treatment is better at treating the cancer than the best treatment available today. About clinical trials was the most needed education topic by patients, survivors, and caregivers who participated in the zero education survey and had been living with the disease for some al trials follow strict guidelines and are highly controlled and regulated to provide the best protection to participants. However placebos are almost never used in cancer treatment the links below to learn more about other aspects of clinical al trial ed consent and patient less of which group they are in, all patients receive the same level of medical attention and care. In most clinical trials, the health of the participants is monitored both during and after the study period. Many clinical trials are successful in finding promising new treatments for prostate cancer, such as the alsympca trial described by dr.
Alicia morgans in the video al trials have helped hundreds of thousands of people – who are alive today – because new, more effective treatments became available. It’s important to take charge of your health and educate yourself about clinical trials. A survey of 2,000 cancer survivors conducted by the coalition of cancer cooperative groups and northwestern university in 2006 found only 12 percent of men were aware of prostate cancer clinical trials while being treated for the g a clinical g to your health care team about available clinical trails is a good first step. In addition, there are trusted resources available to help you find a clinical can call the national cancer institute’s (nci) help line at 800-4-cancer to help search the national databases for trial information. The nci also maintains an online listing of cancer clinical trials at /clinicaltrials/ national institutes of health maintains which is a database of publicly and privately supported clinical and other available databases allow you to conduct a very detailed search of all cancer clinical trials. The nci’s and listings are the most complete lists of cancer clinical trials be recruited for a clinical trial or survey, you can register for research match, a free program that connects people trying to find research studies with researchers looking for study there are hundreds of clinical trials available for prostate cancer, below are some trials that are currently recruiting study will evaluate the safety and efficacy of enzalutamide (xtandi) in men with nonmetastatic castration-resistant prostate cancer. The trial will enroll men with prostate cancer that is progressing despite androgen deprivation therapy, but who have no symptoms of disease and have no prior or present evidence of metastatic disease. Click here to download the prosper trial trial is for men who are newly diagnosed with hormone sensitive metastatic prostate cancer and have a psa level of at least 2ng/ml. To visit the sponsor website, click purpose of this study is to determine the safety and effectiveness of a new drug in delaying prostate cancer spreading from the prostate. This study is enrolling prostate cancer patients with rising psa levels whose prostate cancer is at risk of progressing but has not already spread to other areas of the body. To visit the sponsor website, click purpose of this study is to determine whether dcvac added onto standard of care chemotherapy can improve survival times in patients with metastatic castration-resistant prostate cancer. Click here for more information about this trial on of enzalutamide plus adt versus placebo plus adt in patients with metastatic hormone sensitive prostate purpose of this study is to evaluate the efficacy of enzalutamide (xtandi) plus androgen deprivation therapy as measured by radiographic progression-free survival.
Click here for more information about this trial on purpose of this study is to assess the safety and efficacy of enzalutamide (xtandi) plus leuprolide (lupron) in patients with nonmetastatic prostate cancer. Candidates for this study have nonmetastatic cancer that is progressing after a radical prostatectomy, radiotherapy, or both. Click here to visit the sponsor purpose of this trial is to determine the effectiveness of rucaparib (rubraca) versus the physician’s choice of therapy in treating men with metastatic castration-resistant prostate cancer. Candidates for this study have metastatic castration-resistant prostate cancer as well as a brca1/2 or atm gene mutation and have not been treated with chemotherapy at this stage. Click here for more information about this trial on purpose of this study is to obtain information on the safety and effectiveness of the tulsa-pro system, which is designed to destroy prostate tissue under mri guidance using ultrasound energy. Candidates for this study are men ages 45 to 80 who have been diagnosed with early-stage, low- or intermediate-risk prostate cancer. Click here to visit the sponsor primary purpose of this study is to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance. Click here for more information about this trial on al trials you considering a clinical trial? Beer covers everything you need to know about clinical : webinars and : maintaining a healthy : questions for your : prostate cancer 360 offers free, comprehensive support for prostate cancer t with your community and register for an event near your hand and join the movement to end prostate er, we can end prostate prostate is prostate cancer? Into the causes, prevention, detection, and treatment of prostate is ongoing in many medical centers throughout the research on gene changes linked to prostate cancer is helping scientists better understand how prostate cancer develops. Tests to find abnormal prostate cancer genes could also help identify men at high risk who might benefit from screening or from chemoprevention trials, which use drugs to try to keep them from getting of the gene mutations that have been studied as factors that might increase prostate cancer risk are from chromosomes that are inherited from both parents. Some research has found that a certain variant of mitochondrial dna, which is inherited only from a person’s mother, might also raise a man’s risk of developing prostate chers continue to look for foods (or substances in them) that can help lower prostate cancer risk.
Scientists have found some substances in tomatoes (lycopenes) and soybeans (isoflavones) that might help prevent prostate cancer. Some studies have found that men with high levels of vitamin d seem to have a lower risk of developing the more lethal forms of prostate cancer. Overall though, studies have not found that vitamin d protects against prostate people assume that vitamins and other natural substances are safe to take, but recent research has shown that high doses of some may be harmful, including those in supplements marketed specifically for prostate cancer. For example, one study found that men who take more than 7 multivitamin tablets per week may have an increased risk of developing advanced prostate cancer. Another study showed a higher risk of prostate cancer in men who had high blood levels of omega-3 fatty acids. Fish oil capsules, which some people take to help with their heart, contain large amounts of omega-3 fatty research has suggested that men who take a daily aspirin for a long time might have a lower risk of getting and dying from prostate cancer. Still, more research is needed to confirm this, and to confirm that any benefit outweighs potential risks, such as ists have also tested certain hormonal medicines called 5-alpha reductase inhibitors as a way of reducing prostate cancer risk. The results of these studies are discussed in prostate cancer prevention and early s agree that the prostate-specific antigen (psa) blood test is not a perfect test for finding prostate cancer early. It misses some cancers, and in other cases the psa level is high even when prostate cancer can’t be found. Researchers are working on strategies to address this approach is to try to improve on the test that measures the total psa level, as described in prostate cancer prevention and early r approach is to develop new tests based on other forms of psa, or other tumor markers. Several newer tests seem to be more accurate than the psa test, including:The phi, which combines the results of total psa, free psa, and propsa to help determine how likely it is that a man has prostate cancer that might need 4kscore test, which combines the results of total psa, free psa, intact psa, and human kallikrein 2 (hk2), along with some other factors, to help determine how likely a man is to have prostate cancer that might need such as progensa that look at the level of prostate cancer antigen 3 (pca3) in the urine after a digital rectal exam (dre). The higher the level, the more likely that prostate cancer is that look for an abnormal gene change called tmprss2:erg in prostate cells in urine collected after a dre.
This gene change is found in some prostate cancers, but it is rarely found in the cells of men without prostate mmdx, which is a test that looks at certain genes in the cells from a prostate biopsy tests aren’t likely to replace the psa test any time soon, but they might be helpful in certain situations. For example, some of these tests might be useful in men with a slightly elevated psa, to help determine whether they should have a prostate biopsy. Some of these tests might be more helpful in determining if men who have already had a prostate biopsy that didn’t find cancer should have another biopsy. Doctors and researchers are trying to determine the best way to use each of these s doing prostate biopsies often rely on transrectal ultrasound (trus), which creates black and white images of the prostate using sound waves, to know where to take samples from. It may make prostate biopsies more accurate by helping to ensure the right part of the gland is even newer technique may enhance color doppler further. Promising results have been reported, but more studies will be needed before its use becomes s are also studying whether mri can be combined with trus to help guide prostate biopsies in men who previously had negative trus-guided biopsies but when the doctor still suspects ining the stage (extent) of prostate cancer plays a key role in determining a man’s treatment options. But imaging tests for prostate cancer such as ct and mri scans can’t detect all areas of cancer, especially small areas of cancer in lymph nodes. Newer method known as multiparametric mri can be used to help determine the extent of the cancer and how aggressive it might be, which might affect a man’s treatment options. The results of the different scans are then taken into r newer method, called enhanced mri, may help find lymph nodes that contain cancer cells. Newer type of positron-emission tomography (pet) scan that uses radioactive carbon acetate instead of labeled glucose (sugar) may also be helpful in detecting prostate cancer in different parts of the body, as well as helping to determine if treatment is working. This technique is now being treatments are being developed, and improvements are being made among many standard prostate cancer treatment s are constantly improving the surgical techniques used to treat prostate cancer. The goal is to remove all of the cancer while lowering the risk of complications and side effects from the described in radiation therapy for prostate cancer, advances in technology are making it possible to aim radiation more precisely than in the past.
Treatments for early stage chers are looking at newer forms of treatment for early-stage prostate cancer. These new treatments could be used either as the first type of treatment or after radiation therapy in cases where it was not treatment, known as high-intensity focused ultrasound (hifu), destroys cancer cells by heating them with highly focused ultrasonic beams. Its safety and effectiveness are now being ion and lifestyle studies have looked at the possible benefits of specific nutrients (often as supplements) in helping to treat prostate cancer, although most of this research is still ongoing. Larger studies are now looking for possible effects of pomegranate juices and extracts on prostate cancer encouraging early results have also been reported with flaxseed supplements. One small study in men with early prostate cancer found that daily flaxseed seemed to slow the rate at which prostate cancer cells multiplied. Recent study showed that taking soy supplements after surgery (radical prostatectomy) for prostate cancer did not lower the risk of the cancer coming study has found that men who choose not to have treatment for their localized prostate cancer may be able to slow its growth with intensive lifestyle changes. Some of these may be helpful even if standard forms of hormone therapy are no longer examples include abiraterone (zytiga) and enzalutamide (xtandi), which are described in hormone therapy for prostate cancer. These drugs are being studied to treat prostate cancer, either to supplement active surveillance or if the psa level rises after s in recent years have shown that many chemotherapy drugs can affect prostate cancer. Some, such as docetaxel (taxotere) and cabazitaxel (jevtana) have been shown to help men live s from recent large studies have found that in men with metastatic prostate cancer, giving chemotherapy (docetaxel) earlier in the course of the disease might help them live longer. These results are encouraging, but these studies were done before newer forms of hormone therapy (abiraterone and enzalutamide) became available, so it’s not clear if the results would be the same new chemo drugs and combinations of drugs are being studied as goal of immunotherapy is to boost the body’s immune system to help fight off or destroy cancer vaccines against infections like measles or mumps, prostate cancer vaccines are designed to help treat, not prevent, prostate cancer. An example of this type of vaccine is sipuleucel-t (provenge), which has received fda approval (described in vaccine treatment for prostate cancer). Other types of vaccines to treat prostate cancer are being tested in clinical example is prostvac, which uses a virus that has been genetically modified to contain prostate-specific antigen (psa).
The patient’s immune system should respond to the virus and begin to recognize and destroy cancer cells containing psa. But newer drugs that target these checkpoints hold a lot of promise as cancer example, newer drugs such as pembrolizumab (keytruda) and nivolumab (opdivo) target the immune checkpoint protein pd-1. In some other cancers, these types of drugs have been shown to shrink a larger portion of tumors. Studies are now being done to see how well they might work against prostate r example is the drug ipilimumab (yervoy), which targets a checkpoint protein called ctla-4 on certain immune cells. This drug is already used to treat some other cancers, and is now being tested in men with advanced prostate promising approach for the future might be to combine a checkpoint inhibitor with a prostate cancer vaccine. This might strengthen the immune response and help the vaccine work ed therapy drugs are being developed that target specific parts of cancer cells or their surrounding environments. Each type of targeted therapy works differently, but all alter the way a cancer cell grows, divides, repairs itself, or interacts with other example, drugs called angiogenesis inhibitors target the growth of new blood vessels (angiogenesis) that tumors need to grow. Several angiogenesis inhibitors are being tested in clinical ng cancer that has spread to the s are studying the use of radiofrequency ablation (rfa) to help control pain in men whose prostate cancer has spread to one or more areas in the bones. Still, early results are american cancer society medical and editorial content team is made up of doctors and master’s-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical all references for prostate medical review: february 16, 2016 last revised: march 11, an cancer society medical information is copyrighted material. We review all feedback and work to provide a better you need immediate assistance, please call 1-800-227-2345, any time day or you would like to unsubscribe/opt out from our communications, please follow this link:Home » clinical trials » search clinical eutic areas: oncology | nephrology | urology | family te cancer clinical trials. Multinational, randomised, double-blind, placebo-controlled, phase iii efficacy and safety study of bay1841788 (odm-201) in men with high-risk non-metastatic castration-resistant prostate y centers of od alabama you have high-risk, localized or locally advanced prostate cancer that requires radiation therapy? Clinical trial seeking patients for a research study for the treatment of nonmetastatic castration-resistant prostate cancer, prostate cancer or cancer of the prostate (embark).
Phase 2 clinical study for patients with prostate gham alabama ts are needed to participate in a clinical research study evaluating incb057643 for the treatment of advanced gham alabama ts are needed to participate in a clinical research study of enzalutamide and active surveillance to evaluate prostate od alabama 35209. Phase 3 clinical study for patients with prostate cancer, advanced prostate cancer and cardiovascular od alabama ts are needed to participate in a clinical research study of enzalutamide and active surveillance to evaluate prostate onal locations alaska. Multinational, randomised, double-blind, placebo-controlled, phase iii efficacy and safety study of bay1841788 (odm-201) in men with high-risk non-metastatic castration-resistant prostate age alaska 99503. Phase 3 clinical study for patients with prostate cancer, advanced prostate cancer and cardiovascular age alaska ts are needed to participate in a clinical research study evaluating relugolix and leuprolide acetate for the treatment of prostate onal locations arizona. Multinational, randomised, double-blind, placebo-controlled, phase iii efficacy and safety study of bay1841788 (odm-201) in men with high-risk non-metastatic castration-resistant prostate onal locations arizona. Randomized, double-blind, placebo controlled phase iii study of odm-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate cancer. Century dale arizona you have high-risk, localized or locally advanced prostate cancer that requires radiation therapy? Clinical research study of ipatasertib, abiraterone and placebo for the treatment of metastatic prostate x arizona 85004. Clinical trial seeking patients for a research study for the treatment of prostate x arizona ts are needed to participate in a clinical research study evaluating lhrh agonist/antagonist, bicalutamide and radium-223 dichloride for the treatment of prostate cancer, bone metastases or prostate dale arizona 85054. Phase 2 clinical study for patients with prostate dale arizona ts are needed to participate in a clinical research study evaluating cc-486 (oral azacitidine) and dale arizona ts are needed to participate in a clinical research study evaluating ec1169 for the treatment of prostate dale arizona ts are needed to participate in a clinical research study of abbv-075. Phase 3 clinical study for patients with prostate cancer, advanced prostate cancer and cardiovascular ts are needed to participate in a clinical research study evaluating cc-486 (oral azacitidine) and ts are needed to participate in a clinical research study evaluating relugolix and leuprolide acetate for the treatment of prostate ts are needed to participate in a clinical research study of enzalutamide and active surveillance to evaluate prostate ts are needed to participate in a clinical research study of enzalutamide and active surveillance to evaluate prostate ts are needed to participate in a clinical research study of enzalutamide, abiraterone acetate and prednisone to evaluate prostate oro arkansas 72401. Clinical trial seeking patients for a research study for the treatment of prostate rock arkansas 72205.
Clinical trial seeking patients for a research study for the treatment of prostate onal locations california. Multinational, randomised, double-blind, placebo-controlled, phase iii efficacy and safety study of bay1841788 (odm-201) in men with high-risk non-metastatic castration-resistant prostate onal locations california. Randomized, double-blind, placebo controlled phase iii study of odm-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate california mr-guided focused ultrasound treatment of localized intermediate risk prostate angeles california you have high-risk, localized or locally advanced prostate cancer that requires radiation therapy? Of california los angeles california mr-guided focused ultrasound treatment of localized intermediate risk prostate ogical sciences david geffen school of medecine at angeles california (tulsa-pro® ablation clinical trial ) is an mri-guided transurethral ultrasound ablation in patients with localized prostate reputable research institutions across the us, canada and europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate rd university school of rd california mr-guided focused ultrasound treatment of localized intermediate risk prostate h california 94531. Clinical trial seeking patients for a research study for the treatment of prostate field california 93301. Clinical trial seeking patients for a research study for the treatment of prostate ght © 1995-2017 centerwatch.
